Arie Belldegrun, MD, FACS
Vice Chairman, Board of Directors
Chairman, Scientific Advisory Board
Cougar Biotechnology, Inc.
Chief, Division of Urologic Oncology
David Geffen School of Medicine at UCLA

Dr. Belldegrun joined Cougar Biotechnology, Inc. in December 2003 as Vice Chairman of the Board of Directors and Chairman of the Scientific Advisory Board. Dr. Belldegrun is Chief of the Division of Urologic Oncology and holds the Roy and Carol Doumani Chair in Urologic Oncology at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA).

He is also the Founder of Agensys, Inc., a privately held biotechnology company focused on the development of fully human monoclonal antibodies to treat solid tumor cancers based on Agensys’ proprietary targets. Dr. Belldegrun served as founding Chairman of Agensys from 1997-2002 and currently serves on Agensys’ Board of Directors and as a consultant.

He completed his medical degree at the Hebrew University Hadassah Medical School in Jerusalem, his post graduate fellowship at the Weizmann Institute of Science and his residency in Urology at Harvard Medical School. Prior to UCLA, Dr. Belldegrun was at the National Cancer Institute/NIH as a research fellow in surgical oncology under Steven A. Rosenberg, MD, PhD. He is certified by the American Board of Urology and a Fellow of the American College of Surgeons.

Dr Belldegrun is also on the scientific boards of several biotechnology and pharmaceutical companies and serves as a reviewer for many medical journals and granting organizations including the Journal of Urology and the American Foundation of Urologic Diseases. In addition to holding several patents, Dr. Belldegrun is the author of several books on prostate and kidney cancers and has written over 250 scientific publications with an emphasis on urologic oncology, particularly kidney, prostate and bladder cancers.

Lindsay A. Rosenwald, MD
Chairman, Founder
Paramount Capital, Inc.

Dr. Rosenwald is the Chairman and Chief Executive of the Paramount Capital group of companies. The Paramount Capital group of companies specializes in asset management, investment banking, venture capital and direct investing within the biotechnology and life-sciences industry. Paramount Capital Asset Management, Inc. manages investor assets through domestic and offshore hedge funds, as well as private equity. Paramount Capital Inc., a NASD member broker dealer, specializes in conducting private placement offerings for public and private development stage biotechnology companies. Paramount Capital Investments, LLC is a venture capital organization that takes a controlling interest in public and private companies, including start-ups and distressed turn-around companies.

Dr. Rosenwald has been a Wall Street biotechnology entrepreneur for over 17 years and has been instrumental in the founding and re-capitalization of dozens of public and private biotechnology and life-sciences companies. Paramount’s portfolio companies have already seen three new chemical entities approved by the FDA and currently have dozens of compounds in clinical trials. One portfolio company, PolaRx BioPharmaceuticals, Inc., received final marketing approval for its cancer drug, Arsenic Trioxide, only 30 months after the first patient was treated in a corporate clinical trial, a record in the industry. In addition to Cougar Biotechnology, Dr. Rosenwald has financed or founded Cypress Bioscience, Inc., Bradley Pharmaceuticals, Inc., Genta, Inc, Repligen Corporation, Discovery Laboratories, Inc., Avigen, Inc., Indevus Pharmaceuticals, Inc., Cardiome Pharma Corp., Keryx Biopharmaceuticals, Inc., Neose Technologies Inc., Cell Therapeutics, Inc., Biocryst Pharmaceuticals, Inc and Hudson Health Sciences, Inc.

Dr. Rosenwald received his M.D. from Temple University School of Medicine and his B.S. in Finance from Pennsylvania State University.

Alan H. Auerbach
Chief Executive Officer/President
Cougar Biotechnology, Inc.

Mr. Auerbach joined Cougar Biotechnology, Inc. in May 2003 as Chief Executive Officer and President. From June 1998 to April 2003, Mr. Auerbach was Vice President, Senior Research Analyst at Wells Fargo Securities where he was responsible for research coverage of small and middle capitalization biotechnology companies, with a focus on companies in the field of oncology. He had primary responsibility for technical, scientific and clinical due diligence as well as selection of biotechnology companies followed by Wells Fargo Securities. During 2002, Mr. Auerbach ranked second in the NASDAQ/Starmine survey of analyst performance for stock picking in biotechnology. From August 1997 to May 1998, Mr. Auerbach was Vice President, Research Analyst at the Seidler Companies, Inc., where he was responsible for research coverage of small capitalization biotechnology companies. Prior to his work as a biotechnology analyst, Mr. Auerbach worked for Diagnostic Products Corporation, where he designed and implemented clinical trials in the field of oncology.

Mr. Auerbach received his B.S. in biomedical engineering from Boston University and his M.S. in biomedical engineering from the University of Southern California.

David M. Tanen

David M. Tanen is currently a partner in Two River Group Holdings, LLC, a New York based venture capital group focused on creating new companies to in-license and develop novel technologies. From 1996 until September 2004, Mr. Tanen has served as an associate director of Paramount Capital, Inc., where he has helped found other biotechnology companies. Mr. Tanen also serves as a member of the Board of Directors of Chiral Quest Inc. (OTCBB: CQST) and Manhattan Pharmaceuticals, Inc. (OTCBB: MHTT) both publicly traded companies, and as an officer and/or director of several other privately held development-stage biotechnology companies. Mr. Tanen received the B.A. degree from George Washington University, and the J.D. degree from Fordham University School of Law.

Harold J. Meyers

Mr. Meyers' career encompasses over 45 years of professional experience in various aspects of the financial services industry, including being the founder of Los Angeles based H.J. Meyers and Company from 1982-1994, serving as Managing Director of Wells Fargo Investments (formerly Van Kasper & Company) from 1995-2003 and serving in his current position as Senior Vice President of A.G. Edwards & Sons, Inc., since 2003. Mr. Meyers holds a B.S. from the University of Denver.